Neuronetics Inc. logo

Neuronetics Inc. (STIM)

Market Open
8 Dec, 20:54
NASDAQ (NMS) NASDAQ (NMS)
$
1. 29
-0.06
-4.07%
$
101.7M Market Cap
- P/E Ratio
0% Div Yield
650,866 Volume
-0.92 Eps
$ 1.35
Previous Close
Day Range
1.26 1.37
Year Range
1.05 5.92
Want to track STIM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 85 days

Summary

STIM trading today lower at $1.29, a decrease of 4.07% from yesterday's close, completing a monthly decrease of -11.9% or $0.18. Over the past 12 months, STIM stock lost -21.52%.
STIM is not paying dividends to its shareholders.
The last earnings report, released on Nov 11, 2025, exceeded the consensus estimates by 0.13%. On average, the company has surpassed earnings expectations by 0.07%, based on the last three reports. The next scheduled earnings report is due on Mar 03, 2026.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

STIM Chart

Similar

Voya CBRE Real Estate Portfolio Class S Mutual Fund
$ -
-
Bold Eagle Acquisition Corp
$ 11.16
+2.2%
Omega Flex, Inc.
$ 27.65
-0.43%
Backblaze Inc.
$ 4.99
0%
Mountain Lake Acquisition Corporation
$ 11
0%
Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates

Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.29 per share a year ago.

Zacks | 1 month ago
Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript

Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Keith J. Sullivan - President, CEO & Director Steven E.

Seekingalpha | 4 months ago
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.33 per share a year ago.

Zacks | 4 months ago

Neuronetics Inc. (STIM) FAQ

What is the stock price today?

The current price is $1.29.

On which exchange is it traded?

Neuronetics Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is STIM.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 101.7M.

When is the next earnings date?

The next earnings report will release on Mar 03, 2026.

Has Neuronetics Inc. ever had a stock split?

No, there has never been a stock split.

Neuronetics Inc. Profile

Professional Services Industry
Industrials Sector
Keith J. Sullivan CEO
NASDAQ (NMS) Exchange
64131A105 CUSIP
US Country
716 Employees
- Last Dividend
- Last Split
28 Jun 2018 IPO Date

Overview

Neuronetics, Inc. is a pioneer in the medical technology industry, focusing on the development and marketing of innovative solutions for patients suffering from neurohealth disorders. Established in 2001 and based in Malvern, Pennsylvania, the company has made significant strides in offering advanced therapeutic options for individuals diagnosed with major depressive disorder, primarily in the United States and internationally. Neuronetics stands out for its dedication to non-invasive, office-based treatments that aim to improve the quality of life for patients struggling with mental health conditions without the need for systemic medications or invasive procedures.

Products and Services

  • NeuroStar Advanced Therapy System

    This flagship product from Neuronetics represents a groundbreaking approach to treating adult patients with major depressive disorder. The NeuroStar Advanced Therapy System utilizes transcranial magnetic stimulation (TMS) technology to produce a pulsed, MRI-strength magnetic field. This field induces electrical currents in specific areas of the brain associated with mood regulation, thereby stimulating these regions to alleviate depressive symptoms. The system is designed for non-invasive and non-systemic treatment, making it an appealing option for patients seeking alternatives to traditional antidepressant medications or those who have not responded well to other therapies. Neuronetics markets this innovative therapy through a dedicated sales and customer support team, focusing on psychiatrists as the primary channel for distribution.

Contact Information

Address: 3222 Phoenixville Pike
Phone: 610 640 4202